Patients Say Genzyme Mischaracterizes Diluted-Drug Claims
By Kelly Knaub ( February 17, 2016, 6:16 PM EST) -- Patients with a life-threatening genetic disorder pushed the First Circuit on Tuesday to revive their putative class action claiming Sanofi subsidiary Genzyme Corp. watered down doses of Fabrazyme and caused their disease to progress faster, saying Genzyme mischaracterized their claims that taking the purportedly diluted drug was worse than not taking any....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.